Bruce Booth (@LifeSciVC) header
Bruce Booth (@LifeSciVC) profile picture

Early stage biotech VC. Recovering scientist. Opinions expressed are solely my own and do not express the views or opinions of Atlas Venture.

Cambridge, MA
Joined December 2010
Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)
Bruce Booth retweeted
Another incredible quarter from the @KymeraTx team: KT-579 - first in human data for the first ever IRF5 directed investigational medicine showing: - complete degradation of IRF5 - placebo-like safety - deep inhibition of inflammatory cytokines, interferon signaling and B-cell markers - onto a Lupus Ph1b study now KT-621 - completed last patient last visit in Broaden2, our global Ph2b AD study, with data before year end. - more details on our call.. Thanks to our amazing team, patients and partners!
Today we shared our third quarter 2026 financial results and reported positive data from the Phase 1 healthy volunteer trial of KT-579, our investigational, first-in-class, oral IRF5 degrader. Join our video webcast today to learn more about this novel program and how we’re advancing an industry-leading pipeline of oral medicines in immunology with the potential to transform patients’ lives: bit.ly/4koh5U1 #RevolutionizingImmunology
2
2
28
4,071
Bruce Booth retweeted
As someone who has helped companies pioneering the use of AI for drug discovery, this is BS. Sure, AI is a tool that we all should deploy to the best of our abilities, but the idea that AI is going to unveil new medicines at a stunning rate the way it will upend cinema, video games, financial services, advertising, gambling, etc., is a bit absurd. New medicine discovery will be one of the laggards in terms of AI revolution. Healthcare provision, diagnostics, and paperwork streamlining will all move ahead faster. Biology will continue to eat everything, AI included.
Anthropic's S-1 is out Its first highlighted potential use of AI: "profoundly accelerate the rate of progress in biology and medicine, potentially curing diseases that have plagued humanity for millennia ..." sec.gov/Archives/edgar/data/…
9
22
3
146
15,434
We’re happy to announce John O’Malley, M.D., Ph.D., as CMO. John’s deep immunology expertise spans academic research, clinical practice, and leadership roles at CRISPR Therapeutics, Sanofi, and Brigham and Women’s Hospital. Welcome to the team, John! bit.ly/4s3R6D6
1
1
1
1,388
Bruce Booth retweeted
Reach The Beach 2026 got cancelled….  Ragnar didn’t pay its bills and NH refused the permits… but our team, Runners Drugs & Money, was ready to go.  We trained over 7000 miles since June.  We raised $128K for charity.  We were ready with plenty of booyah and cowbell.  And we did a fun run & breakfast together yesterday anyway. It just was not to be for 2026. Bummed, as it’s the best running event of the year. We’ll be ready for 2027! #RTB2026 #RunningAtlas
5
3
56
9,927
Bruce Booth retweeted
a nice longform writeup from bruce booth arguing why it would be a mistake to ban US-china IP licensing.
Patient-first, America-first: The Case For Global Collaboration While the rise of Chinese biopharma in the past decade has been meteoric, I’m firmly in the camp that their engagement in the global ecosystem is good for the sector – its more opportunity than threat, great for patients, and is a healthy forcing function to raise the game for everyone lifescivc.com/2026/06/patien…
2
1
20
11,061
Great analysis by @LifeSciVC! To me, it’s pretty clear that biotech exists to help bring medicines to patients. We should keep patients as our Northstar and welcome innovation from anywhere in the world!
Patient-first, America-first: The Case For Global Collaboration While the rise of Chinese biopharma in the past decade has been meteoric, I’m firmly in the camp that their engagement in the global ecosystem is good for the sector – its more opportunity than threat, great for patients, and is a healthy forcing function to raise the game for everyone lifescivc.com/2026/06/patien…
4
2
27
8,041
Bruce Booth retweeted
👑2️⃣ My ASCO Top 10 Pick #2 OBX-115: engineered TILs with regulatable mbIL15 in ICI-refractory advanced melanoma 💥 ORR 67% (2 CRs) || DCR 93% || DoR NR ✅ No DLTs/ICANS/ICU transfers ▪️ No IL-2 required Small numbers and short follow-up, but this may be one of the most exciting next-generation cell therapy platforms in melanoma!!! AGNI may just have lit the fire 🔥 Congrats to @DrBetofMDPhD and all the team! AMAZING!! 👏🏼 @OncoAlert
16
34
4,993
Bruce Booth retweeted
Early (n=15) OBX-115 (TILs with Acetazolamide regulated membrane bound IL15) Ph2 data in Melanoma/NSCLC looks remarkable: 67% cORR with a CR (and no IL-2 needed!). Here's a mountain sickness drug making T-cells do amazing things. Congrats @Obsidian_Tx asco.org/abstracts-presentat…
5
9
3,433
We’re pleased to share that the FDA has granted Fast Track designation to KT-621, our investigational, first-in-class, oral STAT6 degrader for the treatment of moderate to severe asthma. This designation supports our goal of advancing a novel, once-daily oral medicine with the potential to transform treatment paradigms for millions of patients across multiple Type 2 inflammatory diseases. Learn more in our recent press release: bit.ly/41qxLQj #RevolutionizingImmunology
2
5
2
24
5,959
Bruce Booth on the successes and failures that have shaped the biotech industry — reflecting on past breakthroughs, changes in the funding landscape, and promising drug modalities now in development go.nature.com/4lMxDnl rdcu.be/fbtak
2
16
1
79
12,046
Bruce Booth retweeted
🚨 Your brain is running on just 12 watts right now while processing this sentence. An AI system would need 2.7 billion watts to do the same thing. That's not a typo. The human brain operates on roughly the same amount of power as a dim light bulb, yet it can recognize faces, solve complex problems, create art, and experience emotions simultaneously. Meanwhile, artificial intelligence systems require massive data centers consuming enough electricity to power entire cities just to simulate a fraction of what your brain does effortlessly. Think about what your brain accomplished just reading this far. It decoded symbols into meaning, connected new information to existing memories, probably triggered some emotional responses, and maybe even started forming opinions about AI energy consumption. All while maintaining your heartbeat, breathing, and thousands of other bodily functions. Total power consumption: 12 watts. The most advanced AI systems need server farms filled with thousands of high-powered processors, industrial cooling systems, and backup power supplies. They consume roughly 225 million times more energy than your brain to perform similar cognitive tasks. It's like comparing a bicycle to a freight train in terms of efficiency. This incredible disparity reveals just how remarkably evolution has optimized biological intelligence. Millions of years of natural selection created a thinking machine so efficient it makes our most advanced technology look primitive and wasteful by comparison. Your smartphone uses more power than your brain while being infinitely less capable. Every thought you're having right now represents the pinnacle of energy-efficient computing, wrapped in three pounds of biological tissue that somehow generates consciousness, creativity, and dreams. Nature got there first, and we're still trying to catch up.
371
1,405
202
3,940
171,620
It may be that failure to count competitors stampeding towards your de-risked target is now the single biggest reason drug R&D programs fail in Phase 2 & 3. "Commercial" termination overtakes "efficacy" circa 2019: nature.com/articles/d41573-0… Recent oncology example (TIGIT herding): bmjoncology.bmj.com/content/…
11
22
3
98
25,669
Bruce Booth retweeted
We just showed excellent small molecule binding prediction by a model trained *only* on data we collected ourselves experimentally, something we haven't seen anyone else do. preprint: github.com/Leash-Labs/hermes… blog post: leashbio.substack.com/publis…
2
4
69
6,648
Bruce Booth retweeted
Grateful that Dr. @adamcifu is saying aloud what many of us are thinking about #ResearchWaste and perverse incentives. We need Sensible Research. sensible-med.com/p/please-do…
3
16
4
55
23,215
Kailera and Hengrui Pharma today announced positive topline data from Hengrui’s Phase 2 clinical trial of once-daily oral ribupatide, a GLP-1/GIP receptor dual agonist peptide, in adults living with obesity in China: kailera.com/press-release/ka… #Obesity #ObesityCare #GLP1 #WeightManagement #KaileraTx
2
1
11
5,036
Bruce Booth retweeted
Biotech IPOs value/# are above same period of any year in the last decade outside of 2021. Liquidity also improving. Looking at a sample set of 300+ biotech stocks, daily shares traded is up ~50% since a year ago. Via Leerink $XBI $IBB $BBC
11
1
61
8,604
On today’s final 2025 episode of #BiotechHangout, @daphnezohar, @LifeSciVC, & @EricSchmidt151 will cover general market overview: companies ($IMNM & $KYTX) raising cash after data w/weak post-deal performance – trend or pre-holiday fatigue?, @LifeSciVC’s year in review & 2025/2026 expectations, policy quick hits: latest batch of MFN deals & threats to broaden, FDA staffing, manufacturing (Japan/Korea $900B trade $$), Pediatric Priority Review Voucher program, politicization of FDA: the rise in Commissioner’s National Priority Vouchers ($JNJ), AAP’s loss of HHS funding plus the launch of Vivek Ramaswamy-backed Ambros Therapeutics, $KYTX’s miv-cel data in stiff person syndrome, $NKTR’s Ph2 alopecia results, plus @statnews's best/worst CEOs & much more: nitter.cf/i/spaces/1lPKqvo…
12
4
1
22
7,594
Oral therapies with biologics-like activity are becoming a reality! KT-621 demonstrates that very deep degradation of STAT6 in the blood and skin of AD patients drives changes in Type-2 biomarkers and clinical endpoints that are in line with, or in many cases numerically superior to, published dupilumab data at week 4. The most impressive aspect is the coherence of all measures: - 94–98% degradation in skin and blood - Reductions in all measurable type-2 biomarkers: TARC, IgE, Eotaxin, IL-31 (first time ever shown) in blood; FeNO in lungs (first time ever shown in AD patients); reductions in Th2, Th17, Th22 gene sets in skin - Improvements in all clinical endpoint measures: EASI, vIGA-AD, PPNRS, SCORAD, DLQI, POEM in AD; FeNO and ACQ-5 in comorbid asthma; TNSS and RQLQ in comorbid allergic rhinitis patients - Pristine safety profile Thank you to the amazing team at Kymera, all the collaborators, investigators and patients that have made this possible!
We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: bit.ly/3XJmwR5 #RevolutionizingImmunology
3
5
2
56
19,826
Bruce Booth retweeted
Why one excellent scientist will refuse to work with the Nature Publishing Group @Nature open.substack.com/pub/hxstem…
2
3
3
33
13,169